Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cann GroupASX:CAN EV-to-EBIT is 0.93 as of Jul. 14, 2026. The stock has 7 warning signs investors should review. Among 688 Drug Manufacturers companies, Cann Group ranks better than 96.66% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Cann Group's Enterprise Value for the quarter that ended in Dec. 2025 was A$28.14 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cann Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$22.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cann Group EV-to-EBIT Related Terms
Cann Group EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Cann Group's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cann Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cann Group EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cann Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Cann Group's EV-to-EBIT falls into.
Cann Group's current Enterprise Value is A$20.65 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cann Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$22.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cann Group (ASX:CAN) has a EV-to-EBIT of 0.93 as of Jul. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cann Group and its competitors. According to the industry distribution chart, Cann Group ranks #23 out of 688 companies in the Drug Manufacturers industry, placing it in the top 3.3%.
Is Cann Group's EV-to-EBIT too high?
Cann Group's current EV-to-EBIT is 0.93. The Drug Manufacturers industry median EV-to-EBIT is 15.84. Cann Group's value of 0.93 is 94.1% below this industry median. Based on the distribution chart, Cann Group ranks #23 out of 688 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Cann Group's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cann Group ranks #23 out of 688 companies for EV-to-EBIT. This places Cann Group in the top 3% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.84. Cann Group's value of 0.93 is 94.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.84, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cann Group's current EV-to-EBIT of 0.93 is 94.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cann Group and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cann Group's current EV-to-EBIT is 0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cann Group stock overvalued right now?
Based on GuruFocus' analysis, Cann Group (ASX:CAN) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.00 — trading 80% below its estimated fair value. The current EV-to-EBIT is 0.93 and 94.1% below the Drug Manufacturers industry median of 15.84. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Cann Group (ASX:CAN), the current EV-to-EBIT is 0.93 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cann Group Ltd is engaged in the cultivation of medicinal cannabis for both medicinal and research purposes under the licenses and permits issued to the company, the development and manufacture (via third-party arrangements) of finished product formulations. Geographically, the company operates in Europe and Australia. The company derives maximum revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CAN has been successfully added to your 
